Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
In: Journal of Antimicrobial Chemotherapy (JAC), Jg. 74 (2019), Heft 1, S. 139-148
Online
academicJournal
Zugriff:
Objectives: To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV-coinfected patients, and assess the effects of efavirenz co-administration and a 50% increase in the dose of rifampicin on the pharmacokinetic parameters of isoniazid and acetyl-isoniazid. Methods: TB/HIV-coinfected patients participating in the three-treatment-arm RAFA randomized controlled trial conducted in West Africa were recruited into the pharmacokinetics sub-study. Five serial blood samples were collected on a single visit between 4 and 8 weeks after initiation of antituberculosis treatment. Concentration-time data for isoniazid and acetyl-isoniazid were analysed using non-linear mixed-effects models. Results: Isoniazid concentrations from 150 patients were available for analysis, and 79 of these (53%) also had concentrations of acetyl-isoniazid. Isoniazid pharmacokinetics was best described with a two-compartment disposition model with lagged first-order absorption and elimination using a semi-mechanistic model describing hepatic extraction. The model identified two elimination pathways, separating formation of acetyl-isoniazid from other routes of metabolism. The predicted AUC0-24 is reduced by 29% in patients who are fast acetylators of isoniazid and receiving efavirenz-based ART (6.73 versus 4.68 mg·h/L). In slow acetylators, efavirenz-based ART had no effect on isoniazid exposure (AUC0-24 = 17.5 mg·h/L). Conclusions: Efavirenz-based ART affects the acetylation metabolic pathway amongst rapid acetylators, resulting in reduced exposure to isoniazid. Pharmacokinetics of isoniazid and acetyl-isoniazid were not influenced by the 50% increase in rifampicin dose. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Antimicrobial Chemotherapy (JAC) is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
|
---|---|
Autor/in / Beteiligte Person: | Chirehwa, Maxwell T ; McIlleron, Helen ; Wiesner, Lubbe ; Affolabi, Dissou ; Bah-Sow, Oumou ; Merle, Corinne ; Denti, Paolo ; team, the RAFA ; team, RAFA |
Link: | |
Zeitschrift: | Journal of Antimicrobial Chemotherapy (JAC), Jg. 74 (2019), Heft 1, S. 139-148 |
Veröffentlichung: | 2019 |
Medientyp: | academicJournal |
ISSN: | 0305-7453 (print) |
DOI: | 10.1093/jac/dky378 |
Schlagwort: |
|
Sonstiges: |
|